• Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

  NCT04162665

  TerminatedInterventionalPhase 2Updated Jan 9, 2025
• A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer

  NCT04062058

  Unknown statusInterventionalPhase 2Updated Jan 24, 2022
• Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

  NCT05274945

  CompletedInterventionalPhase 2Updated Mar 11, 2022
• Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer

  NCT06097416

  Not yet recruitingInterventionalPhase 3Updated Oct 25, 2023
• Total Neoadjuvant Therapy in Rectal Cancer

  NCT06162650

  RecruitingInterventionalPhase 2Updated Apr 8, 2026
• Short Course or Long Course Radiotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

  NCT07258797

  Not yet recruitingInterventionalNot ApplicableUpdated Dec 2, 2025

ClinicalTrials.gov ID

NCT07101666

Lead Sponsor

Washington University School of MedicineOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

20Estimated

Last Update Posted

Aug 6, 2026Actual

Start Date

Oct 31, 2026Estimated

Primary Completion Date

Apr 30, 2031Estimated

Completion Date

Apr 30, 2031Estimated

Official Title

Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer

Brief Summary

Standard treatment for patients with early stage gastric cancer consists of perioperative chemotherapy and surgical resection. If radiation therapy is administered in the adjuvant setting, the radiated area is often large and associated with significant toxicity.

In this study, the investigators propose the addition of short course radiation therapy (SCRT) to chemotherapy in the neoadjuvant setting. The investigators hypothesize that this regimen of Total Neoadjuvant Therapy (TNT) will result in a higher rate of complete response (both pathologic and clinical), with less toxicity.

• Gastric Cancer

• Short course radiation therapy
• Standard of care neoadjuvant chemotherapy

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Newly diagnosed histologically or cytologically gastric adenocarcinoma. (Siewert III acceptable: the bulk of tumor should be in stomach; gastric tumors with extension to the gastroesophageal junction are permitted.) Patients with T1-4N0-3 are eligible.

• Known T-stage defined by EUS. Must have had CT of the chest/abdomen/pelvis with IV contrast (or PET/CT if unable to receive iodinated contrast).

• Medically eligible to receive SOC chemotherapy.

• At least 18 years of age.

• ECOG performance status ≤ 2.

• Adequate bone marrow and organ function as defined below:

  • Absolute neutrophil count ≥ 1.5 K/cumm
  • Platelets ≥ 100 K/cumm
  • Creatinine clearance > 50 mL/min by Cockroft Gault calculation

• The effects of the various chemotherapy agents used in this study on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and one month after completion of the study.

• Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion Criteria:

• Prior surgery, radiation, or chemotherapy for gastric or esophageal cancer.
• Prior surgery to the esophagus or stomach.
• Siewert I-II GE junction tumor.
• Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.
• Currently receiving any other investigational agents.
• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to the SOC chemotherapy used in the study.
• Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia that are considered clinically significant as determined by the treating physician.
• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of study entry.
• HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Washington University School of MedicineOTHER

855-903-1098